Amgen's Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Some of Amgen’s key businesses are drawing concerns as competition looms.

Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watchers’ current expectations, Mizuho analyst Salim Syed warned in a Monday note to investors.

The company’s biosimilars franchise, PCSK9 cholesterol drug Repatha and inflammatory disease therapy Otezla could become its weak points, Syed said.